Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ALK rearrange |
Therapy | Deulorlatinib |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK rearrange | lung non-small cell carcinoma | sensitive | Deulorlatinib | Phase I | Actionable | In a Phase I/Ib trial, Deulorlatinib (TGRX-326) treatment demonstrated safety in non-small cell lung cancer patients harboring an ALK rearrangement and led to an objective response rate (ORR) of 71.4% (10/14) and disease control rate (DCR) of 100% in Xalkori (crizotinib)-pretreated patients, an ORR of 87.9% (29/33) and DCR of 97.0% (32/33) in TKI-naive patients, and an ORR of 38.1% (37/97) and DCR of 81.4% (79/97) in patients pre-treated with second-generation TKIs (PMID: 39551469; NCT05441956). | 39551469 |
PubMed Id | Reference Title | Details |
---|---|---|
(39551469) | Safety, efficacy and biomarker analysis of deulorlatinib (TGRX-326) in ALK-positive non-small-cell lung cancer: a multicentre, open-label, phase 1/1b trial. | Full reference... |